Bardet-Biedl Syndrome
FDA expands setmelanotide approval for rare forms of obesity to children aged 2 to 5 years
The FDA approved an expanded indication for setmelanotide to include children aged 2 to 5 years with several genetic forms of obesity, Rhythm Pharmaceuticals announced.
People with Bardet-Biedl syndrome lower metabolic syndrome score with setmelanotide
DALLAS — Setmelanotide may lower the risk for metabolic syndrome for people with a rare monogenic form of obesity, according to data presented at ObesityWeek.
Setmelanotide reduces hyperphagia, improves quality of life in Bardet-Biedl syndrome
Treatment with the melanocortin-4 receptor agonist setmelanotide reduced hyperphagia and led to improvements in emotional well-being among children and adults with Bardet-Biedl syndrome, according to study findings.
Setmelanotide significantly reduces body weight for people with Bardet-Biedl syndrome
Setmelanotide led to significant reductions in weight among people with obesity and the genetic disorder Bardet-Biedl syndrome, but not Alström syndrome, according to findings published in The Lancet Diabetes & Endocrinology.
FDA approves setmelanotide for patients with Bardet-Biedl syndrome
The FDA has cleared a melanocortin-4 receptor agonist for chronic weight management in people with a rare genetic disease of obesity, according to an industry press release.
Rare obesity disorders call for genetic testing, targeted therapies
Severe obesity starting early in life is a hallmark of rare genetic disorders of obesity. A genetic diagnosis can alleviate feelings of guilt or blame and lessen social stigma for youths with these disorders and their families.